EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence

Salvatore Crisafulli, Brigida Boccanegra iD, Giacomo Vitturi, Gianluca Trifirò iD, Annamaria De Luca iD

Brain Sciences · 10.10.2023 · 13 (10) · 1446

DOI: 10.3390/brainsci13101446 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 10.10.2023. Verfasst von Salvatore Crisafulli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Verona, Piazzale Ludovico Antonio Scuro 10, 37124 Verona, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a rare neuromuscular disease, with an estimated incidence of about 1 in 10,000 live births. To date, three orphan drugs have been approved for the treatment of SMA: nusinersen, onasemnogene abeparvovec, and risdiplam. The aim of this narrative review was to provide an overview of the pre- and post-marketing evidence on the pharmacological treatments approved for the treatment of SMA by identifying preclinical and clinical studies registered in clinicaltrials.gov and in the EU PAS register from their inception until the 4 January 2023. The preclinical evidence on the drugs approved for SMA allowed a significant acceleration in the experimental phase of these drugs. However, since these drugs had been authorized through accelerated programs, the conduction of post-marketing studies was requested as a condition of their marketing approval to better understand their risk–benefit profiles in real-world settings. As of the 4 January 2023, a total of 69 post-marketing studies concerning the three orphan drugs approved for SMA were identified in clinicaltrials.gov (N = 65; 94.2%) and in the EU PAS register (N = 4; 5.8%). Currently, ongoing studies are primarily aimed at providing evidence concerning the risk–benefit profile of the three drugs in specific populations that were not included in the pivotal trials and to investigate the long-term safety and clinical benefits of these drugs. Real-world data sources collecting information regarding the natural history of the disease and post-marketing surveillance of the available therapies are increasingly becoming essential for generating real-world evidence on this rare disease and its orphan drugs.

Schlagwörter

Stichwörter der Autor:innen

nusinersenonasemnogene abeparvovecpost-marketing evidencepre-marketing evidencerisdiplamspinal muscular atrophy

Autor:innen und Institutionen

  • Department of Medicine, University of Verona, Piazzale Ludovico Antonio Scuro 10, 37124 Verona, Italy.
  • Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, 70125 Bari, Italy.
  • Department of Diagnostics and Public Health, University of Verona, Piazzale Ludovico Antonio Scuro 10, 37124 Verona, Italy.

ORCID-Profile: Brigida Boccanegra, Gianluca Trifirò, Annamaria De Luca

Zitieren

APA

Crisafulli, S., Boccanegra, B., Vitturi, G., Trifirò, G., & De Luca, A. (2023). Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence. Brain Sciences, 13(10), 1446. https://doi.org/10.3390/brainsci13101446

Vancouver

Crisafulli S, Boccanegra B, Vitturi G, Trifirò G, De Luca A. Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence. Brain Sciences. 2023;13(10):1446. doi:10.3390/brainsci13101446

BibTeX
@article{Crisafulli2023,
  author = {Crisafulli, Salvatore and Boccanegra, Brigida and Vitturi, Giacomo and Trifirò, Gianluca and De Luca, Annamaria},
  title = {Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence},
  journal = {Brain Sciences},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {1446},
  doi = {10.3390/brainsci13101446}
}
Kostenlos starten →